ApoGen is focused on developing a new class of therapeutics that target drivers of cancer genomic mutations, specifically the APOBEC cytidine deaminases, an antiviral component of the human innate immune system implicated in producing cancer mutations. The company is pursuing inhibition of APOBEC-induced mutagenesis as a mechanism to prevent development of resistance to cancer therapies. ApoGen raised an additional $4m in Series A financing, bringing total Series A funding to $11m. M Ventures and existing investors provided the new funding. The company plans to use the expanded Series A to hire additional staff and establish a laboratory in Seattle. Recent leadership additions include Stephen Gwaltney, PhD, as vice president of chemistry and Peter de Vries, PhD, as senior director of biology. ApoGen Biotechnologies is developing a new class of therapeutics aimed at drivers of cancer genomic mutation, specifically the APOBEC family of cytidine deaminases. Its core product effort is discovery and development of highly selective, potent small‑molecule inhibitors of APOBEC enzymes and companion diagnostics to identify patients most likely to benefit. The company holds a worldwide, exclusive license from the University of Minnesota to a portfolio of APOBEC technologies developed by its scientific founders. ApoGen’s team includes University of Minnesota investigators and an experienced life‑science entrepreneur, and it has assembled a scientific advisory board of leading cancer and chemical‑biology investigators. The company intends to advance its programs toward clinical and commercial development to slow or stop tumor evolution and therapy resistance. Financially, ApoGen announced a $7 million Series A financing to support its drug discovery and development efforts.

Total raised

$11M

Funding rounds

2

Latest round

Series A

Latest activity

Aug 2018